glyburide has been researched along with vildagliptin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| El-Ouaghlidi, A; Foley, J; Holmes, D; Holst, JJ; Nauck, MA; Rehring, E; Schweizer, A | 1 |
| Balez, S; Bullock, J; Dole, WP; He, YL; Jarugula, V; Ligueros-Saylan, M; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Casali, KR; Fofonka, A; Ribeiro, JP; Schaan, BD | 1 |
| Berlanda, G; Bock, PM; Casali, KR; da Rosa, FM; da Silveira, AD; Fofonka, A; Schaan, BD | 1 |
| Cesarino, CB; Cosenso-Martin, LN; Fernandes, LAB; Giollo-Júnior, LT; Machado, MN; Nakazone, MA; Vilela-Martin, JF; Yugar-Toledo, JC | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
1 review(s) available for glyburide and vildagliptin
| Article | Year |
|---|---|
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
5 trial(s) available for glyburide and vildagliptin
| Article | Year |
|---|---|
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Topics: Adamantane; Adult; Algorithms; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glyburide; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2008 |
Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
Topics: Adamantane; Biomarkers; Blood Glucose; Brazil; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Exercise Test; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Nitriles; Oxidative Stress; Predictive Value of Tests; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2014 |
Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Female; Glucose; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2018 |
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glyburide; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Pulse Wave Analysis; Vascular Stiffness; Vildagliptin | 2018 |
2 other study(ies) available for glyburide and vildagliptin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glyburide; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2013 |